[HTML][HTML] Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?

M Lawrenz, A Visekruna, A Kühl, N Schmidt… - Mucosal …, 2012 - Elsevier
Inflammatory bowel disease is characterized by dysregulated immune responses against
intestinal microflora leading to marked activation of nuclear factor-κB (NF-κB) with
subsequent production of pro-inflammatory cytokines. Besides NF-κB, the tumor progression
locus 2 (TPL-2)/extracellular signal-regulated kinase (ERK) pathway also regulates
inflammatory cytokines such as interleukin-1β and tumor necrosis factor-α, but its role during
intestinal inflammation is incompletely understood. We analyzed the impact of TPL-2 in the …